Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Parisi  R, Symmons  DP, Griffiths  CE, Ashcroft  DM; Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) Project Team.  Global epidemiology of psoriasis: a systematic review of incidence and prevalence.   J Invest Dermatol. 2013;133(2):377-385. doi:10.1038/jid.2012.339 PubMedGoogle Scholar
2.
Dalgard  F, Svensson  Å, Gieler  U,  et al.  Dermatologists across Europe underestimate depression and anxiety: results from 3635 dermatological consultations.   Br J Dermatol. 2018;179(2):464-470. doi:10.1111/bjd.16250PubMedGoogle Scholar
3.
Dommasch  ED, Li  T, Okereke  OI, Li  Y, Qureshi  AA, Cho  E.  Risk of depression in women with psoriasis: a cohort study.   Br J Dermatol. 2015;173(4):975-980. doi:10.1111/bjd.14032 PubMedGoogle Scholar
4.
Golpour  M, Hosseini  SH, Khademloo  M,  et al.  Depression and anxiety disorders among patients with psoriasis: a hospital-based case-control study.   Dermatol Res Pract. 2012;2012:381905. doi:10.1155/2012/381905 PubMedGoogle Scholar
5.
Gottlieb  AB, Chao  C, Dann  F.  Psoriasis comorbidities.   J Dermatolog Treat. 2008;19(1):5-21. doi:10.1080/09546630701364768 PubMedGoogle Scholar
6.
Hayes  J, Koo  J.  Psoriasis: depression, anxiety, smoking, and drinking habits.   Dermatol Ther. 2010;23(2):174-180. doi:10.1111/j.1529-8019.2010.01312.x PubMedGoogle Scholar
7.
Kimball  AB, Gladman  D, Gelfand  JM,  et al; National Psoriasis Foundation.  National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.   J Am Acad Dermatol. 2008;58(6):1031-1042. doi:10.1016/j.jaad.2008.01.006 PubMedGoogle Scholar
8.
Langley  RGB, Krueger  GG, Griffiths  CEM.  Psoriasis: epidemiology, clinical features, and quality of life.   Ann Rheum Dis. 2005;64(suppl 2):ii18-ii23. doi:10.1136/ard.2004.033217 PubMedGoogle Scholar
9.
Kurd  SK, Troxel  AB, Crits-Christoph  P, Gelfand  JM.  The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.   Arch Dermatol. 2010;146(8):891-895.PubMedGoogle Scholar
10.
Bernklev  T, Jahnsen  J, Lygren  I, Henriksen  M, Vatn  M, Moum  B.  Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms.   Inflamm Bowel Dis. 2005;11(10):909-918. doi:10.1097/01.mib.0000179467.01748.99PubMedGoogle Scholar
11.
Hare  DL, Toukhsati  SR, Johansson  P, Jaarsma  T.  Depression and cardiovascular disease: a clinical review.   Eur Heart J. 2014;35(21):1365-1372. doi:10.1093/eurheartj/eht462PubMedGoogle Scholar
12.
Pan  A, Keum  N, Okereke  OI,  et al.  Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies.   Diabetes Care. 2012;35(5):1171-1180. doi:10.2337/dc11-2055PubMedGoogle Scholar
13.
Rubin  RR, Peyrot  M.  Quality of life and diabetes.   Diabetes Metab Res Rev. 1999;15(3):205-218. doi:10.1002/(SICI)1520-7560(199905/06)15:3<205::AID-DMRR29>3.0.CO;2-OPubMedGoogle Scholar
14.
Stark  D, Kiely  M, Smith  A, Velikova  G, House  A, Selby  P.  Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life.   J Clin Oncol. 2002;20(14):3137-3148. doi:10.1200/JCO.2002.08.549PubMedGoogle Scholar
15.
Euesden  J, Danese  A, Lewis  CM, Maughan  B.  A bidirectional relationship between depression and the autoimmune disorders: new perspectives from the National Child Development Study.   PLoS One. 2017;12(3):e0173015. doi:10.1371/journal.pone.0173015 PubMedGoogle Scholar
16.
Grozdev  I, Korman  N, Tsankov  N.  Psoriasis as a systemic disease.   Clin Dermatol. 2014;32(3):343-350. doi:10.1016/j.clindermatol.2013.11.001PubMedGoogle Scholar
17.
Horowitz  MA, Zunszain  PA, Anacker  C, Musaelyan  K, Pariante  CM. Glucocorticoids and inflammation: a double-headed sword in depression? In: Halaris A, Leonard BE, eds.  Inflammation in Psychiatry. 28th ed. Karger Publishers; 2013:127-143. Accessed April 27, 2020. https://www.karger.com/Book/Toc/257496 doi:10.1159/000343980
18.
Maes  M, Kubera  M, Obuchowiczwa  E, Goehler  L, Brzeszcz  J.  Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways.   Neuro Endocrinol Lett. 2011;32(1):7-24.PubMedGoogle Scholar
19.
Vogelzangs  N, de Jonge  P, Smit  JH, Bahn  S, Penninx  BW.  Cytokine production capacity in depression and anxiety.   Transl Psychiatry. 2016;6(5):e825. doi:10.1038/tp.2016.92 PubMedGoogle Scholar
20.
Cohen  BE, Martires  KJ, Ho  RS.  Psoriasis and the risk of depression in the US population: National Health and Nutrition Examination Survey 2009-2012.   JAMA Dermatol. 2016;152(1):73-79. doi:10.1001/jamadermatol.2015.3605 PubMedGoogle Scholar
21.
Jensen  P, Ahlehoff  O, Egeberg  A, Gislason  G, Hansen  PR, Skov  L.  Psoriasis and new-onset depression: a Danish nationwide cohort study.   Acta Derm Venereol. 2016;96(1):39-42. doi:10.2340/00015555-2183PubMedGoogle Scholar
22.
Roell  KR, Reif  DM, Motsinger-Reif  AA.  An introduction to terminology and methodology of chemical synergy: perspectives from across disciplines.   Front Pharmacol. 2017;8:158. doi:10.3389/fphar.2017.00158 PubMedGoogle Scholar
23.
World Medical Association.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.   JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053PubMedGoogle Scholar
24.
Ferreira-González  I, Permanyer-Miralda  G, Busse  JW,  et al.  Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns.   J Clin Epidemiol. 2007;60(7):651-657. doi:10.1016/j.jclinepi.2006.10.020 PubMedGoogle Scholar
25.
Elixhauser  A, Steiner  C, Harris  DR, Coffey  RM.  Comorbidity measures for use with administrative data.   Med Care. 1998;36(1):8-27. doi:10.1097/00005650-199801000-00004PubMedGoogle Scholar
26.
Charlson  ME, Pompei  P, Ales  KL, MacKenzie  CR.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.   J Chronic Dis. 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8 PubMedGoogle Scholar
27.
Austin  SR, Wong  YN, Uzzo  RG, Beck  JR, Egleston  BL.  Why summary comorbidity measures such as the Charlson Comorbidity Index and Elixhauser score work.   Med Care. 2015;53(9):e65-e72. doi:10.1097/MLR.0b013e318297429cPubMedGoogle Scholar
28.
Gutacker  N, Bloor  K, Cookson  R.  Comparing the performance of the Charlson/Deyo and Elixhauser comorbidity measures across five European countries and three conditions.   Eur J Public Health. 2015;25(suppl 1):15-20. doi:10.1093/eurpub/cku221PubMedGoogle Scholar
29.
Southern  DA, Quan  H, Ghali  WA.  Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data.   Med Care. 2004;42(4):355-360. doi:10.1097/01.mlr.0000118861.56848.eePubMedGoogle Scholar
30.
Li  B, Evans  D, Faris  P, Dean  S, Quan  H.  Risk adjustment performance of Charlson and Elixhauser comorbidities in ICD-9 and ICD-10 administrative databases.   BMC Health Serv Res. 2008;8:12. doi:10.1186/1472-6963-8-12PubMedGoogle Scholar
31.
Feldman  SR, Zhao  Y, Shi  L, Tran  MH, Lu  J.  Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.   Arthritis Care Res (Hoboken). 2015;67(5):708-717. doi:10.1002/acr.22492PubMedGoogle Scholar
32.
Yeung  H, Takeshita  J, Mehta  NN,  et al.  Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.   JAMA Dermatol. 2013;149(10):1173-1179. doi:10.1001/jamadermatol.2013.5015PubMedGoogle Scholar
33.
Gottlieb  AB, Dann  F.  Comorbidities in patients with psoriasis.   Am J Med. 2009;122(12):1150.e1-1150.e9. doi:10.1016/j.amjmed.2009.06.021PubMedGoogle Scholar
34.
Takeshita  J, Grewal  S, Langan  SM,  et al.  Psoriasis and comorbid diseases: implications for management.   J Am Acad Dermatol. 2017;76(3):393-403. doi:10.1016/j.jaad.2016.07.065PubMedGoogle Scholar
35.
Chi  CC, Chen  TH, Wang  SH, Tung  TH.  Risk of suicidality in people with psoriasis: a systematic review and meta-analysis of cohort studies.   Am J Clin Dermatol. 2017;18(5):621-627. doi:10.1007/s40257-017-0281-1PubMedGoogle Scholar
36.
Matterne  U, Baumeister  SE, Apfelbacher  CJ.  Suicidality and risk of suicidality in psoriasis: a critical appraisal of two systematic reviews and meta-analyses.   Br J Dermatol. 2019;181(4):717-721. doi:10.1111/bjd.18108 PubMedGoogle Scholar
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    June 3, 2020

    Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study

    Author Affiliations
    • 1Division of Dermatology, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
    • 2Quantify Research, Stockholm, Sweden
    • 3Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
    • 4Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
    • 5Department of Clinical Sciences, Umeå University, Umeå, Sweden
    JAMA Dermatol. 2020;156(7):795-804. doi:10.1001/jamadermatol.2020.1398
    Key Points

    Question  How are skin psoriasis and somatic comorbidity associated with the development of psychiatric illness?

    Findings  Among 93 239 patients with skin psoriasis and 1 387 495 control participants in this matched case-control study, skin psoriasis and somatic comorbidity were independently associated with 1.32 and 2.09 times increased risk, respectively, of psychiatric illness onset compared with control participants without psoriasis and without somatic comorbidity. Skin psoriasis and somatic comorbidity acted additively but not synergistically.

    Meaning  Proactive, holistic treatment of patients with psoriasis is recommended because treating skin symptoms alone cannot remedy the elevated risk for psychiatric comorbidity.

    Abstract

    Importance  Psoriasis is a complex systemic disease with skin involvement, somatic comorbidity, and psychiatric illness (PI). Although this view of psoriasis is widely accepted, potential synergies within this triad of symptoms have not been adequately investigated.

    Objectives  To investigate the independent association of skin psoriasis and somatic comorbidity with the development of PI and to assess whether skin psoriasis and somatic comorbidity act synergistically to produce a risk of PI that is greater than the additive associations.

    Design, Setting, and Participants  Participants were enrolled between January 2005 and December 2010, in this retrospective matched case-control study using secondary (ie, administrative), population-based registry data from Swedish patients in routine clinical care. The dates of analysis were March 2017 to December 2019. Participants were patients with skin psoriasis and control participants without psoriasis matched on age, sex, and municipality, who were all free of preexisting PI.

    Exposures  Presence of skin psoriasis and somatic comorbidity (captured through the Charlson Comorbidity Index and the Elixhauser Comorbidity Index).

    Main Outcomes and Measures  Risk of PI onset (composite of depression, anxiety, and suicidality) is shown using Kaplan-Meier curves stratified by the presence of skin psoriasis and somatic comorbidity. Adjusted associations of skin psoriasis and somatic comorbidity with the development of PI were analyzed using Cox proportional hazards regression models, including interactions to assess synergistic associations. The 3 components of PI were also assessed individually.

    Results  A total of 93 239 patients with skin psoriasis (mean [SD] age, 54 [17] years; 47 475 men [51%]) and 1 387 495 control participants (mean [SD] age, 54 [16] years; 702 332 men [51%]) were included in the study. As expected, patients with skin psoriasis were more likely to have somatic comorbidity and PI than control participants. Compared with those without skin psoriasis or somatic comorbidity, patients with psoriasis without somatic comorbidity had a 1.32 times higher risk of PI onset (hazard ratio [HR], 1.32; 95% CI, 1.27-1.36; P < .001), whereas patients with psoriasis with somatic comorbidity had a 2.56 times higher risk of PI onset (HR, 2.56; 95% CI, 2.46-2.66; P < .001). No synergistic associations of skin psoriasis and somatic comorbidity with the development of PI were found (HR, 0.93; 95% CI, 0.81-1.04; P = .21).

    Conclusions and Relevance  This study found that somatic comorbidity appeared to alter PI onset even more than skin psoriasis. The observed association of skin psoriasis and somatic comorbidity with the development of PI reinforces the need for proactive, holistic treatment of patients with psoriasis.

    ×